⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Monte Rosa Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Monte Rosa Therapeutics
↗Boston, USA
Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing molecular glue degrader (MGD) medicines. The company utilizes its proprietary QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform, which integrates AI, structural biology, and proteomics to identify and rationally design small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade disease-causing proteins.
The company's pipeline targets serious diseases in oncology, autoimmune, and inflammatory areas. Headquartered in Boston, Massachusetts, with additional research operations in Basel, Switzerland, Monte Rosa is a publicly traded company (NASDAQ: GLUE) dedicated to expanding the druggable target space for previously 'undruggable' proteins.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology/Immunology/Inflammation
SIZE & FINANCIALS
Employees:51-200
Founded:2018
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Versant Ventures
STOCK
Exchange:NASDAQ
Ticker:GLUE
Market Cap:$2.05B
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1/2
Modalities:Small molecule, Molecular Glue Degraders
Active Trials:3
Trial Phases:Phase 1: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Various undisclosed pharmaceutical collaborations in immunology, oncology, and neurology
COMPETITION
Position:Emerging
Competitors:C4 Therapeutics, Kymera Therapeutics, Arvinas
LEADERSHIP
Key Executives:
Markus Warmuth - CEO
LINKS
Website:monterosatx.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Monte Rosa Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.